- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07940023
Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma (CCuCC-1)
Phase Ib to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma
This trial is a phase I trial in patients with metastasized castration resistant prostate cancer (mCRPC) after failure of at least third-line therapy aiming to evaluate safety and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity. CC-1 binds to human prostate-specific membrane antigen (PSMA) on prostate cancer cells as well as to tumor vessels of CRPC, thereby allowing for a dual mode of anti-cancer action. CC-1 was developed in a novel format which not only prolongs serum half-life but most importantly reduces off-target T cell activation with expected fewer side effects. Together with pre-emptive IL-6 receptor (IL-6R) blockade using tocilizumab, this allows for application of effective bsAb doses with expected high anticancer activity. The maximum tolerated dose (MTD) of once per week subcutaneously (SC) applied CC-1 has been established in the DKTK_PMO_1605 trial. This is a phase Ib trial to further explore the efficacy and safety of the MTD of SC CC-1.
A translational research program comprising, among others, analysis of CC-1 half-life and molecular profiling in liquid biopsies will serve to better define the mode of action of CC-1 and to identify biomarkers for further clinical development.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
CRCP is an aggressive malignant disease with poor prognosis after failure of established therapies. Any drug employed after third-line treatment is associated with only limited clinical benefit. Therefore, there is a high medical need for new therapeutic approaches in this patient population. While progress has been made in the field of immunotherapeutics for other tumor types, no relevant progress in immunotherapeutic options in CRPC has been achieved over the last years. In general, the target antigen PSMA is expressed abundantly on prostate cancer cells. However, loss of expression reportedly is associated with duration of ADT treatment or neuroendocrine differentiation. Accordingly and to avoid invasive procedures like needle biopsy, PSMA expression on tumor lesions must be confirmed by PSMA-PET prior to treatment with CC-1. The phase I trial is designed to confirm and further explore the safety and tolerability of the PSMAxCD3 bsAb CC-1 in adult patients with CRPC after third-line therapy. The primary objective is incidence and severity of adverse events (AEs) under therapy with CC-1. Furthermore, the trial aims to expand experience on pharmacokinetics, pharmacodynamics and toxicology of CC-1 from nonclinical studies to the human situation in relation to the PK, expected efficacy and safety. A focus will be on the following specific aspects/parameters:
- Assessment of response rate by RECIST on routine imaging
- Absolute changes from baseline in the tumor marker (PSA)
- Overall and progression free survival
- Pharmacokinetics and pharmacodynamics of CC-1 in humans
- Immunogenicity of CC-1 in humans based on both absolute (number and percentage of subjects who develop anti-drug antibody (ADA).
The rationale for the therapeutic use of CC-1 is based on its proposed mode of action as a bsAb being specifically designed to direct T cells via its CD3 binding part towards tumor target cells via its PSMA binding part. Furthermore, CC-1 also reacts with tumor vessels of CRPC thereby allowing for a dual mode of anti-cancer action by also attacking tumor blood supply and allowing for improved influx of immune effector cells. Due to its unique ability to redirect T cells via CD3 for PSMA-expressing tumor cell lysis, CC-1 can elicit repeated target cell elimination by cytotoxic T cells and a polyclonal response of previously primed CD4+ and CD8+ T cells. Compared to other immunotherapeutics presently being approved or in development (bsAbs with alternative formats like the authorised bsAb blinatumomab or other antibodies or CART cells), CC-1 is expected to offer the following major advantages:
(i) Reduction of off-target T cell activation and thus reduction of side effects due to its optimized format (ii) The possibility to tightly steer anti-target activity via serum level-controlled antibody application which, in contrast to CART cells, allows for termination of activity if desired.
On the background of the poor prognosis of patients with CRPC after third-line therapy, the bsAb CC-1 holds promise as a new treatment option of immunotherapy for these patients.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Juliane Walz, Prof. Dr.
- Puhelinnumero: +49 (0)7071 29-83275
- Sähköposti: kketi@med.uni-tuebingen.de
Opiskelupaikat
-
-
Baden-Wurttemberg
-
Tübingen, Baden-Wurttemberg, Saksa, 72076
- University Hospital Tuebingen
-
Ottaa yhteyttä:
- CCU Translational Immunology
- Puhelinnumero: +49 (0)7071 29-83275
- Sähköposti: kketi@med.uni-tuebingen.de
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Existence of a written informed consent
-
Patient aged ≥ 18, no upper age limit
-
Patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
-
Metastatic CRPC after at least third line treatment
-
Disease progression confirmed by tumor marker or/and imaging
-
Serum testosterone levels <50 ng/dl (1.7 nM)
-
At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment
-
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
-
Male patients with partners of child-bearing potential, who are sexually active, must agree to the use of two highly effective forms of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 3 months after the last dose of study drug.
-
PSMA-positivity of CRPC as determined by PSMA-PET
-
Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:
- Hemoglobin ≥ 9 g/dl (Transfusion of packed red blood cells prior to enrolment allowed)
- Neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/µl
- Bilirubin ≤ 1.5 x upper limit of normal (ULN)
- ALT and AST ≤ 2.5 x ULN
- PT-INR/PTT ≤ 1.5 x ULN
- Creatine kinase ≤ 2.5 x ULN
- Serum creatinine ≤1.5 mg/dl or creatinine clearance ≥ 60 ml/min
-
Exclusion Criteria:
-
Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer.
- Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy
- Persistent toxicity (≥Grade 2 according to Common Terminology Criteria for Adverse Events [CTCAE] version 6.0) caused by previous cancer therapy, excluding alopecia and neurotoxicity (≤ 2 grade)
- Clinically significant xerostomia (dry mouth >1grade according to CTCAE V6.0)
- CNS manifestation of the tumor or tumor manifestation close to the CNS (e.g. spinal cord) as assessed by the investigator
- Clinical signs of active infection (> grade 2 according to CTCAE version 6.0)
- History of HIV infection
- Immunocompromised patients
- Viral active or chronic hepatitis (HBV or HCV)
- History of autoimmune disease
- History of relevant CNS pathology or current relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)
- Epilepsy requiring pharmacologic treatment
- Therapeutic anticoagulation therapy
- Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery.
- Patients receiving any systemic chemotherapy or radiotherapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used
- Heart failure NYHA III/IV
- Non-controlled hypertension, defined as mean blood pressure values of >130 mmHg or >90 mmHg for systolic or diastolic, respectively
- Severe obstructive or restrictive ventilation disorder
- Known history of GI-perforation
- Known intolerance to CC-1, tocilizumab or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in the respective drug products (CC-1, tocilizumab)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: CC-1 s.c.
The patients will receive CC-1 weekly as SC injection. In the first week of treatment step dosing (T1V1: (P1), T1V2: (P2), T1V3: target dose level (TDL)) are applied. For the first week of treatment patient will be treated as an inpatient until 48h after application of the first target dose at visit T1V3. Thereafter the TDL will be applied weekly. For the second application of the TDL of CC-1 (first application without step dosing) at T2V1 patient again will be treated as an inpatient until 24h after CC-1 application. If well tolerated and upon medical evaluation, the T3V1 and following doses may be administered in an out-patient setting |
The patients will receive CC-1 weekly as SC injection. Tocilizumab is applied at visit T1V1 and thereafter upon occurrence of CRS ≥grade 2. Tocilizumab is applied at least 1h prior to SC CC-1 application. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
PSA Response
Aikaikkuna: Baseline, Cycle 1 Visit 1, Cycle 2 Visit 1, Cycle 3Visit 1, Cycle 4Visit1, (...) Cycle 16 Visit1, End of treatment, Follow Up visit, End of Study
|
PSA serum levels must be determined during screening, on the day of first CC-1 treatment prior to treatment (= baseline) and thereafter once per week during treatment, at End Of Treatment visit (7 days after previous CC-1 administration), Follow Up visit (28 days after End-of-Treatment Visit) and End-Of-Study Visit (28 days after the Follow-Up Visit). PSA serum levels for one study patient are assessed in the same lab during the whole study treatment. |
Baseline, Cycle 1 Visit 1, Cycle 2 Visit 1, Cycle 3Visit 1, Cycle 4Visit1, (...) Cycle 16 Visit1, End of treatment, Follow Up visit, End of Study
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- NCT_CCUCC_001
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .